Accessibility StatementSkip Navigation BELLEVUE, Wash., Nov. 21, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), today announced that Vaximm AG, an OSR Company, has entered into a non-binding term sheet with BCM Europe AG ("BCME"), a Swiss-based life sciences investment group and OSRH's largest shareholder, to explore a potential exclusive global licensing agreement for VXM01, Vaximm's first-in-class oral cancer immunotherapy platform. The term sheet establishes a six-month exclusivity period during ...

Core Insights - OSR Holdings, Inc. has appointed Dr. Andreas Niethammer as the new CEO of Vaximm AG, effective December 1, 2025, marking a significant leadership change in the company [1][4] - Dr. Niethammer is recognized for his expertise in oncology and has been instrumental in developing Vaximm's oral T-cell immunotherapy platform, particularly the lead candidate VXM01 targeting VEGFR-2 [2][5] - The company plans to integrate its anti-angiogenic immune activation platform with viral oncolysis technologies to enhance its immuno-oncology offerings, with a strategic collaboration expected to be announced soon [3][4] Company Overview - Vaximm AG is a Swiss-German biotechnology company focused on oral T-cell vaccination, utilizing live, attenuated bacterial vectors to induce immune responses against tumors [5] - The lead therapeutic candidate, VXM01, has shown clinical activity and safety across multiple cancer types, particularly in pancreatic cancer and glioblastoma [2][5] - OSR Holdings, Inc. is a global healthcare holding company that supports biomedical innovations across various sectors, including immuno-oncology and regenerative biologics [6]

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price TargetOctober 20, 2025 11:40 AM EDT | Source: Emerging Growth ResearchNew York, New York--(Newsfile Corp. - October 20, 2025) - Emerging Growth Research today announced the initiation of coverage on OSR Holdings, Inc. (NASDAQ: OSRH) with a Buy-Emerging rating and a 12-month price target of $10.00, representing over 1,600% upside from the Company's recent closing price of $0.58.The init ...

Group 1: Appointment of Dr. Andreas Niethammer - OSR Holdings, Inc. has appointed Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, focusing on the development of orally administered T-cell activators, including VXM01, an anti-VEGFR-2 candidate in clinical stages [1][2] - Dr. Niethammer is an internationally recognized expert in oncology with over 20 years of experience in cancer immunotherapy and clinical development, having held leadership roles in several global biopharmaceutical companies [2][4] Group 2: Vaximm AG and its Focus - Vaximm AG, a wholly owned subsidiary of OSR Holdings, is a Swiss-German biotech company dedicated to developing oral T-cell immunotherapies for cancer, with its lead program VXM01 having completed Phase I/II clinical trials for pancreatic cancer and glioblastoma [5][6] - The company aims to activate targeted cytotoxic T-cell responses through oral administration, representing a novel approach in cancer treatment [5] Group 3: Future Directions and Vision - Dr. Niethammer expressed optimism about accelerating the development of oral immunotherapies with the potential to improve outcomes for patients with challenging cancers and other diseases with high unmet needs [4] - OSR Holdings envisions acquiring and operating a portfolio of innovative healthcare companies to enhance patient care through advanced research and development [6]